Bleeding Risk Related to Upper Gastrointestinal Endoscopic Biopsy in Patients Receiving Antithrombotic Therapy: A Multicenter Prospective Observational Study

Takafumi Yuki, MD, PhD1, Shunji Ishihara, MD, PhD2,*, Kazuo Yashima, MD, PhD3, Koichiro Kawaguchi, MD, PhD3, Hirofumi Fujishiro, MD, PhD4, Youichi Miyaoka, MD, PhD5, Mika Yuki, MD, PhD6, Yoshinori Kushiyama, MD, PhD7, Akiko Yasugi, MD, PhD8, Michiko Shabana, MD, PhD9, Koichirou Furuta, MD, PhD10, Kiwamu Tanaka, MD, PhD11, Masaharu Koda, MD, PhD12, Tetsuro Hamamoto, MD, PhD13, Yuichiro Sasaki, MD, PhD14, Hisao Tanaka, MD, PhD15, Teiji Yoshimura, MD, PhD16, Yoshikazu Murawaki, MD, PhD3, Hajime Isomoto, MD, PhD3, Yoshikazu Kinoshita, MD, PhD2

1 Gastrointestinal Endoscopy, Shimane University Hospital, Izumo, Japan
2 Department of Internal Medicine II, Shimane University Faculty of Medicine, Izumo, Japan
3 Division of Medicine and Clinical Science, Faculty of Medicine, Tottori University, Yonago, Japan
4 Division of Gastroenterology, Shimane Prefectural Central Hospital, Izumo, Japan
5 Division of Gastroenterology, Shimane Prefectural Central Hospital, Izumo, Japan
6 Department of Internal Medicine, Izumo-City General Medical Center, Izumo, Japan
7 Division of Gastroenterology, Matsue Red Cross Hospital, Matsue, Japan
8 Division of Gastroenterology, National Hospital Organization Hamada Medical Center, Hamada, Japan
9 Division of Gastroenterology, Sanin Rosai Hospital, Yonago, Japan
10 Division of Gastroenterology, Masuda Red Cross Hospital, Masuda, Japan
11 Division of Gastroenterology, Tottori Prefectural Central Hospital, Tottori, Japan
12 Division of Gastroenterology, Yonago Medical Center, Yonago, Japan
13 Division of Gastroenterology, Hakuai Hospital, Yonago, Japan
14 Division of Gastroenterology, Tottoriken Saiseikai Sakaiminato General Hospital, Sakaiminato, Japan
15 Division of Gastroenterology, Tottori Prefectural Central Hospital, Tottori, Japan
16 Division of Gastroenterology, Tottori Red Cross Hospital, Tottori, Japan
17 Division of Gastroenterology, Matsue City Hospital, Matsue, Japan

ARTICLE INFO

Article history: Accepted 31 March 2017

Key words: antiplatelet drug anticoagulant drug esophagogastroduodenoscopy biopsy gastrointestinal bleeding

ABSTRACT

Background: Although antithrombotic agents are widely used for cardiac and cerebrovascular disease prevention, they increase the risk of gastrointestinal (GI) bleeding.

Objective: To examine GI bleeding risk in association with an esophagogastroduodenoscopy (EGD) biopsy performed in patients without cessation of antithrombotic therapy.

Methods: This study was prospectively conducted at 14 centers. EGD biopsies were performed in patients receiving antithrombotic agents without cessation, as well as age- and sex-matched controls not receiving antithrombotic therapy. Patients treated with warfarin before the biopsy had a prothrombin time-international normalized ratio level < 3.0. The proportion of GI bleeding events was compared between the groups.

Results: The patient group (n = 277) underwent a total of 560 biopsies while continuing antithrombotic therapy, of whom 24 were receiving multiple antiplatelet drugs, and 9 were receiving both antiplatelet and anticoagulant agents. The control patients (n = 263) underwent 557 biopsies. The upper-GI bleeding rate within 30 days after the EGD biopsy did not increase in patients without cessation of antithrombotic therapy. Patients treated with warfarin before the biopsy had a prothrombin time-international normalized ratio level < 3.0. The proportion of GI bleeding events was compared between the groups.

Conclusions: We found no significant increase in upper-GI bleeding risk following an EGD biopsy in patients taking antithrombotic agents, suggesting its safety without the need for antithrombotic treatment interruption. © 2017. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Antithrombotic agents have important roles for medical treatment and prevention of various diseases. Of those, antplatelet drugs such as low-dose aspirin and clopidogrel are used for prevention of cerebrovascular disease and coronary arterial disease.1–4 On the other hand, anticoagulant drugs, including warfarin and direct oral anticoagulants (DOACs) are given for a variety of clinical conditions, such as prevention of recurrent venous thromboembolism and stroke in patients with atrial fibrillation.5–8 Thus, antithrombotic agents have been commonly used in recent years as both primary and secondary drugs to prevent cerebrovascular and coronary diseases in the expanding elderly population.

Although use of antithrombotic agents contributes to prevention of various vascular diseases, patients treated with those are at greater risk of gastrointestinal (GI) bleeding.9–15 Therefore, diagnostic and therapeutic endoscopic procedures should be performed under consideration of bleeding risk. Indeed, cessation of antithrombotic drugs before an endoscopic examination is thought to reduce the risk of GI bleeding.12,13,16–19 However, thrombosis caused by cessation of those drugs is closely associated with more serious complications including increased mortality.

Several retrospective studies have shown that an endoscopic biopsy is not related to increased GI bleeding in patients who continue to use antithrombotic drugs.20–23 In addition, endoscopic biopsy procedures have been safely performed in patients taking warfarin by appropriately controlling the prothrombin time-international normalized ratio (PT-INR).24,25 As a result, recent guidelines for gastrointestinal endoscopy do not recommend cessation of antithrombotic drugs before an endoscopic biopsy.26,27 However, evidence thoroughly showing the safety of an endoscopic biopsy in patients taking antithrombotic agents remains insufficient. To clearly elucidate this issue, we performed the present multicenter prospective observational study to determine bleeding risk in patients undergoing antithrombotic treatment according to guidelines presented by the Japan Gastroenterological Endoscopy Society (JGES).27

Materials and Methods

This study was prospectively conducted from January 2013 to August 2014 at 14 centers (2 university hospitals, 12 general hospitals) in Japan. The study protocol was approved by the Shimane University Institutional Committee on Ethics as well as by the ethics committee of each institution (UMIN000013520). Informed consent was obtained from all patients. All study procedures were carried out in accordance with the JGES guidelines.27

Patients being treated at the participating hospitals who received antplatelet (single or multiple) and/or anticoagulant agents, and who underwent a diagnostic esophagogastroduodenoscopy (EGD) biopsy during the study period were enrolled. The EGD examinations and biopsy procedures were performed by well-trained endoscopy specialists at each hospital who carefully observed the upper-GI tract of their patients and sometimes used magnifying endoscopy for diagnosis when necessary to avoid an unnecessary biopsy. All biopsies were carefully performed using forceps for various reasons, including the presence of symptoms (heartburn, dysphagia, epigastralgia, and discomfort), screening or surveillance of cancer, and closer examination of cancer before endoscopic or surgical therapy. The actual number of samples obtained was used as the number of biopsy procedures in each case. PT-INR level was measured in each patient receiving warfarin within 7 days before EGD and a diagnostic biopsy procedure was permitted when that value was < 3.0. Patients administered DOACs received those drugs on the day of the EGD examination and biopsy procedure. Emergency EGD cases as well as patients with cessation of antithrombotic drugs before the EGD biopsy were excluded from the study. Patients not receiving antithrombotic therapy and who underwent a diagnostic EGD biopsy procedure were enrolled as control patients. We attempted to match the control group by age (± 5 years) and gender with the patients receiving antithrombotic agents at a 1 to 1 ratio. After confirming hemostasis at the biopsy site, the endoscope was removed. The primary outcome of this study was incidence of upper-GI bleeding following an EGD biopsy. Patients who came to the emergency room or outpatient clinic for symptoms such as tarry stool or hematemesis within 30 days after the EGD biopsy underwent a blood test, and those with upper-GI bleeding were confirmed by the presence of anemia.

Statistical analyses were conducted using a χ² test, with a P value < 0.05 considered to be significant. All calculations were performed using SPSS version 19.0 for Windows (IBM-SPSS Inc, Armonk, New York).

Results

A flow chart of the study protocol is presented in Figure 1. We initially enrolled 286 patients who were taking antithrombotic agents, of whom 9 were excluded from analysis due to cessation of antithrombotic agents before EGD. In addition, 263 patients not receiving antithrombotic therapy were enrolled as control patients. The number in the control group was less than that of patients taking antithrombotic agents, because appropriate age- and sex-matched patients could not be found at several of the participating institutions during the study period.

Patient characteristics are shown in Table 1. There were no significant differences in regard to gender or average age between the groups. Details of the antithrombotic drugs used are shown in Table 1. As for anticoagulant agents, warfarin (n = 45) and DOACs (dabigatran, n = 12 and rivaroxaban, n = 7) were given, whereas low-dose aspirin (100 mg, n = 122 and 81 mg, n = 7), clopidogrel (n = 37), ethylicosapentate (n = 21), limaprost alfadex (n = 20), and cilostazol n = 17) were frequently given as antplatelet agents. Twenty-four patients were receiving multiple antplatelet drugs (clopidogrel and aspirin together, n = 5), and 9 were administered both antplatelet and anticoagulant agents. The rates of proton pump inhibitor (PPI) and histamine H2-receptor antagonist

![Figure 1. Flow chart of the study protocol.](image-url)
(H2-blocker) use were significantly higher in patients receiving antithrombotic agents compared with the control group.

The total number of biopsy procedures performed in the group of patients who were receiving antithrombotic agents was 560 (esophagus, n = 96; stomach, n = 447; and duodenum, n = 17) and in the control group that number was 557 (esophagus, n = 90; stomach, n = 452; and duodenum, n = 15). During the follow-up period (within 30 days after the EGD biopsy), we did not find upper-GI bleeding in either group (Table II), although thrombosis was observed in an elderly female patient taking warfarin for treatment of atrial fibrillation and diabetes mellitus. She was hospitalized for a cardiogenic cerebral embolism at 25 days after the biopsy, then recovered with appropriate treatment and was hospitalized for a cardiogenic cerebral embolism at 25 days after the EGD biopsy.

In the present multicenter, prospective, observational study, we investigated the risk of upper-GI bleeding following an EGD biopsy procedure in patients taking antithrombotic agents as well as control group patients without antithrombotic therapy. Our results indicated that use of single or multiple antiplatelet and/or anticoagulant drugs does not increase upper-GI bleeding within 30 days after an EGD biopsy.

When an endoscopic biopsy is performed in patients who have stopped antithrombotic therapy, thromboembolism is a more serious complication and draws more attention than hemorrhage.12,13,16–19 Thus, it is considered important to elucidate the safety of an endoscopic biopsy in patients without cessation of that therapy. Previous studies regarding management of antithrombotic agents in patients undergoing an invasive endoscopic procedure, such as biopsy, polypectomy, endoscopic mucosal resection, or endoscopic submucosal dissection, have revealed a low prevalence of GI bleeding events regardless of antithrombotic therapy.20,21 More recently, a study that focused on the EGD biopsy procedure showed that upper-GI bleeding risk was not increased in patients without cessation of antithrombotic therapy.22 However, those results were obtained from retrospective studies or investigations conducted by a single center or without a control group.

Although several reports have indicated that aspirin alone in standard doses does not increase the rate of bleeding after an endoscopic biopsy,28–30 few prospective studies have appropriately evaluated the safety of antithrombotic therapy in patients undergoing an EGD biopsy. Ono et al.28 investigated hemostasis as well as late-phase bleeding risk in patients taking antithrombotic agents up to 2 weeks after an EGD biopsy, and found a low level of risk for either event in patients who continued antithrombotic therapy. However, that was a single-arm study conducted at a single center. Another prospective study also demonstrated that continuation of antithrombotic agents did not increase bleeding risk after an EGD biopsy.22 Nevertheless, although that was a multicenter investigation, several factors, including age and gender, were different between the comparison groups.

To thoroughly verify the safety of continuing antithrombotic therapy in association with an EGD biopsy, we designed a prospective, multicenter study and enrolled patients who continued antithrombotic therapy during the procedure (n = 277, 560 biopsy procedures), as well as an age- and sex-matched control group who did not receive antithrombotic agents (n = 263, 557 procedures). Our findings clearly showed that hemostasis and late-phase bleeding for up to 30 days after the EGD biopsy did not increase in the patients without cessation of antithrombotic agents regardless of biopsy site, indicating the safety of this procedure while continuing to receive antithrombotic therapy.

Warfarin, an anticoagulant drug, is widely used for prevention of thrombosis and thromboembolism. Previous studies have revealed that bleeding risk in association with an EGD biopsy did not increase in patients with a PT-INR of 3.0.24,25 In this regard, Western guidelines as well as those of the JGES currently recommend performance of an EGD biopsy procedure without cessation of warfarin within that therapeutic range.26,27 In the present study, we investigated patients taking warfarin (PT-INR < 3.0) with or without antiplatelet agents, and found no increase in upper-GI bleeding following an EGD biopsy, which confirmed similar findings reported in recent studies. Thus, we consider that an EGD biopsy can be safely performed in patients taking warfarin alone or that combined with antiplatelet agents who have a controlled INR level. In addition to warfarin, DOACs have been developed as a new anticoagulant type.5–8 In the present as well as other recent

### Table I

| Antithrombotic agent | No. of biopsies | No current antithrombotic therapy | P value |
|----------------------|----------------|-----------------------------------|---------|
| Anticoagulant agent (n = 64) | | | |
| Warfarin | 45 | – | – |
| Dabigatran | 12 | – | – |
| Rivaroxaban | 7 | – | – |
| Antiplatelet agent | | | |
| Low-dose aspirin | 100 mg | 122 | – |
| 81 mg | 7 | – | – |
| Clopidogrel | 37 | – | – |
| Ethylicosapentate | 21 | – | – |
| Limaprost alfadex | 20 | – | – |
| Clopidogrel | 17 | – | – |
| Dipyridamole | 4 | – | – |
| Ticlopidine | 3 | – | – |
| Hydrochloride | 3 | – | – |
| Sarpogrelate | 150 | 75 | < 0.001 |
| Hydrochloride | 41 | 17 | 0.003 |
| Ilenprofill tartrate | 3 | – | – |
| Others | 9 | – | – |
| Multiantiplatelet users† | 24 | – | – |
| Anticoagulant agent users | 9 | – | – |

### Table II

| No. of biopsies | Taking antithrombotic agents without cessation | No current antithrombotic therapy | P value |
|----------------|---------------------------------|---------------------------------|---------|
| Duodenum | 17 | 15 | 0.863 |
| Stomach | 447 | 452 | 0.359 |
| Esophagus | 96 | 90 | 0.950 |
| Histamine H2-receptor antagonist | 41 | 17 | 0.003 |
| Proton pump inhibitor | 150 | 75 | < 0.001 |
| Antacid agent | 41 | 17 | 0.003 |

Values for age are given as mean (SD).

† Clopidogrel and aspirin together (n = 5).

### Discussion

In the present multicenter, prospective, observational study, we investigated the risk of upper-GI bleeding following an EGD biopsy procedure in patients taking antithrombotic agents as well as control group patients without antithrombotic therapy. Our results indicated that use of single or multiple antiplatelet and/or anticoagulant drugs does not increase upper-GI bleeding within 30 days after an EGD biopsy.

When an endoscopic biopsy is performed in patients who have stopped antithrombotic therapy, thromboembolism is a more serious complication and draws more attention than hemorrhage.12,13,16–19 Thus, it is considered important to elucidate the safety of an endoscopic biopsy in patients without cessation of that therapy. Previous studies regarding management of antithrombotic agents in patients undergoing an invasive endoscopic procedure, such as biopsy, polypectomy, endoscopic mucosal resection, or endoscopic submucosal dissection, have revealed a low prevalence of GI bleeding events regardless of antithrombotic therapy.20,21 More recently, a study that focused on the EGD biopsy procedure showed that upper-GI bleeding risk was not increased in patients without cessation of antithrombotic therapy.22 However, those results were obtained from retrospective studies or investigations conducted by a single center or without a control group.

Although several reports have indicated that aspirin alone in standard doses does not increase the rate of bleeding after an endoscopic biopsy,28–30 few prospective studies have appropriately evaluated the safety of antithrombotic therapy in patients undergoing an EGD biopsy. Ono et al.28 investigated hemostasis as well as late-phase bleeding risk in patients taking antithrombotic agents up to 2 weeks after an EGD biopsy, and found a low level of risk for either event in patients who continued antithrombotic therapy. However, that was a single-arm study conducted at a single center. Another prospective study also demonstrated that continuation of antithrombotic agents did not increase bleeding risk after an EGD biopsy.22 Nevertheless, although that was a multicenter investigation, several factors, including age and gender, were different between the comparison groups.

To thoroughly verify the safety of continuing antithrombotic therapy in association with an EGD biopsy, we designed a prospective, multicenter study and enrolled patients who continued antithrombotic therapy during the procedure (n = 277, 560 biopsy procedures), as well as an age- and sex-matched control group who did not receive antithrombotic agents (n = 263, 557 procedures). Our findings clearly showed that hemostasis and late-phase bleeding for up to 30 days after the EGD biopsy did not increase in the patients without cessation of antithrombotic agents regardless of biopsy site, indicating the safety of this procedure while continuing to receive antithrombotic therapy.

Warfarin, an anticoagulant drug, is widely used for prevention of thrombosis and thromboembolism. Previous studies have revealed that bleeding risk in association with an EGD biopsy did not increase in patients with a PT-INR of 3.0.24,25 In this regard, Western guidelines as well as those of the JGES currently recommend performance of an EGD biopsy procedure without cessation of warfarin within that therapeutic range.26,27 In the present study, we investigated patients taking warfarin (PT-INR < 3.0) with or without antiplatelet agents, and found no increase in upper-GI bleeding following an EGD biopsy, which confirmed similar findings reported in recent studies. Thus, we consider that an EGD biopsy can be safely performed in patients taking warfarin alone or that combined with antiplatelet agents who have a controlled INR level. In addition to warfarin, DOACs have been developed as a new anticoagulant type.5–8 In the present as well as other recent
Conclusions

Results of our prospective multicenter study showed no significant increase in the proportion of upper-GI bleeding complications following an EGD biopsy in patients receiving antithrombotic medication, suggesting the safety of such a low-risk procedure without the need to interrupt antithrombotic treatment.

Acknowledgments

The authors thank the staff and patients who participated in this study. No funding source had involvement in the design, analysis, or writing of the manuscript. All authors designed the study protocol and carried out the research. Y. Takafumi, S. Ishihara and Y. Kinoshita performed the statistical analysis and wrote the manuscript. All authors read and approved the final manuscript.

Conflicts of Interest

The authors have indicated that they have no conflicts of interest regarding the content of this article.

References

1. Leon MB, Baim DS, Pomp A, Gordon PC, Curling DE, Ho KK, Giambrone J, A. Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. J Am Coll Cardiol. 1998;33:893-900.

2. Lansberg MG, O’Donnell MJ, Kathiri P, Lang ES, Nguyen-Huyen MN, Schwartz NE, Sonnenberg FA, Schulman S, VANDvik PO, Spencer FA, Alonso-Coello P, Guyatt GH, Ald AE; American College of Chest Physicians. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians-Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e601S–636E.

3. Brighton TA, Eikelboom JW, Mann K, Ritter R, Gallus A, Ockelford P, Gibbs H, Hague W, Xavier D, Diaz R, Kirby A, Simes J, ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2015;372:1979–87.

4. Okada S, Morimoto T, Ogawa H, Sakuma M, Soejima H, Nakayama M, Sugiyama S, Jinnouchi H, Waki M, Doi N, Horii M, Kawata H, Somekawa S, Soeda T, Uemura S, Saito Y. Effect of low-dose aspirin on primary prevention of cardiovascular events in Japanese diabetic patients at high risk. Circ J. 2013;77:3023–8.

5. Xiong Q, Lai YC, Sonnen K, Lane DH, Hong K, Lip GY. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systematic review and meta-analysis of randomized trials. Eur J Heart Fail. 2015;17:1192–200.

6. Rubboli A, Ageval S, Huber K, Lip GY. New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint. Int J Cardiol. 2015;196:133–8.

7. Sonnen K, Lai YC, Drezhlish M, Lane D, Uemura K, Lip GY. Efficacy and safety of non-vitamin K antagonist oral anticoagulants vs. warfarin in Japanese patients with atrial fibrillation – meta-analysis. Circ J. 2015;79:339–45.

8. Gilmour-Oates AM, Terzile-Fernández AI, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E, Dabalgaran, RIORobanor, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups. Thrombosis. 2013;2013:640723, http://dx.doi.org/10.1155/2013/640723. Epub 2013 Dec 22.

9. Svenningsen HT, Mellekjaer L, Blot WJ, Nielsen GL, Steffensen FH, McLaughlin JK, Olsen JH. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 2000;95:2218–24.

10. Yusuf S, Zhao F, Mehta SR, Chrolavics S, Tognoni G, Fox KR. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–5026.

11. Hallas J, Dall M, Andries A, Andersen BS, Aalykke C, Hansen JM, Andersen M, Lassen AT. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ. 2006;333:726;10.

12. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan PKF, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM, Harrington RA, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Hatky MA, Kaul S, Lindner JR, Moliterno DJ, Mukherjee D, Schofill RS, Rosenson RS, Stein Jr, Weitz HH, Wesley DJ. American College of Cardiology FoundationAmerican College of GastroenterologyAmericanHeart Association. ACCF/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation, 118; 2008, 1894–909.

13. Becker RC, Scheiman J, Dauerman HL, Spencer F, Rao S, Sabatine M, Johnson DA, Chan F, Abraham NS, Quigley EM, American College of Cardiology and the American College of Gastroenterology. Management of platelet-directed pharmacotherapy in patients with atherothrombotic disease undergoing elective endoscopic gastrointestinal procedures. J Am Coll Cardiol. 2009;54:2261–76.

14. Antithrombotic Trialists’ (ATT) Collaboration, Bagnett C, Blackwell L, Collins R, Emberson J, Godwin J, Petro R, Burridge J, Hennekens C, Kearney P, Meade T, Patrano C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–60.

15. Metz AJ, Bourke MJ, Moss A, Williams SJ, Swan MP, Bynk K. Factors that predict bleeding following endoscopic mucosal resection of large colorectal lesions. Endoscopy. 2011;43:506–11.

16. Paleroti G, Legnani C, Guazzaloco G, Frascari M, Grauso F, De Rosa F, Fortunato G, Coccheri S. Activation of blood coagulation after abrupt or stepwise withdrawal of oral anticoagulants–a prospective study. Thromb Haemost. 1994;72:222–9.

17. Wahl MJ. Dental surgery in anticoagulated patients. Neurology. 2001;57:1985–8.

18. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Petro R, Burridge J, Hennekens C, Kearney P, Meade T, Patrano C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–60.

19. Blacker DJ, Wijdicks EFM, McClelland RL. Stroke risk in anticoagulated patients with atrial fibrillation undergoing endoscopy. Neurology. 2003;63:964–8.

20. Wijesundara DN, Wijesundara HC, Yun L, Wasowicz M, Beattie WS, Velianou JL, Ko DT. Risk of elective major noncardiac surgery after coronary stent insertion: a population-based study. Circulation. 2012;126:1355–62.

21. Diver DJ, Hsu HC, Fujishiro M, Hirose K, Niimi K, Goto O, Kodashima S, Yamazaki N, Koike K. Retrospective analysis on the management of anticoagulants and antiplatelet agents for scheduled endoscopy. J Gastroenterol. 2009;44:1185–93.

22. Iwatsuka K, Gotoda T, Kusano F, Fukuzawa M, Sugimoto K, Itó T, Kawai T, Moriyasu M. Clinical management of esophagogastroduodenoscopy by clinicians under the former guidelines of the Japan Gastroenterological Endoscopic Society for patients taking anticoagulant and antiplatelet medications. Gastric Cancer. 2014;17:680–5.
23. Shiffman ML, Farrel MT, Vee YS. Risk of bleeding after endoscopic biopsy or polypectomy in patients taking aspirin or other NSAIDS. Gastrointest Endosc. 1994;40:458–62.

24. Gerson LB, Triadafilopoulos G, Gage BF. The management of anticoagulants in the periendoscopic period for patients with atrial fibrillation: a decision analysis. Am J Gastroenterol. 2000;95:1717–24.

25. Gerson LB, Michaels L, Ullah N, Gage B, Williams L. Adverse events associated with anticoagulation therapy in the eridendoscopic period. Gastrointest Endosc. 2010;71:1211–7.

26. ASGE Standards of Practice Committee, Anderson MA, Ben-Menachem T, Gan SI, Appalaneni V, Banerjee S, Cash BD, Fisher L, Harrison ME, Fanelli RD, Fukami N, Ikemurry SO, Jain R, Khan K, Kriensky ML, Lichtenstein DR, Maple JT, Shen B, Strohmeyer L, Baron T, Dominitz JA. Management of antithrombotic agents for endoscopic procedures. Gastrointest Endosc. 2009;70:1060–70.

27. Fujimoto K, Fujishiro M, Kato M, Higuchi K, Iwakiri R, Sakamoto C, Uchiyama S, Kashiwagi A, Ogawa H, Murakami K, Mine T, Yoshino J, Kinoshita Y, Ichinose M, Matsu T; Japan Gastroenterological Endoscopy Society. Guidelines for endoscopic management of non-variceal upper gastrointestinal bleeding. Dig Endosc. 2016;28:363–78.

28. Ono S, Fujishiro M, Kodashima S, Takahashi Y, Minatsuki C, Mikami-Matsuda R, Asada-Hirayama I, Konno-Shimizu M, Tsuji Y, Mochizuki S, Niimi K, Yamamichi N, Kaneko M, Yatomi Y, Koike K. Evaluation of safety of endoscopic biopsy without cessation of antithrombotic agents in Japan. J Gastroenterol. 2012;47:770–4.

29. Ara N, Iijima K, Maejima R, Kondo Y, Kusaka G, Hatta W, Uno K, Asano N, Koike T, Imatani A, Shimosegawa T. Prospective analysis of risk for bleeding after endoscopic biopsy without cessation of antithrombotics in Japan. Dig Endosc. 2015;27:458–64.

30. Whitson MJ, Dikman AE, von Allhann C, Sanyal S, Desai JC, Bamji ND, Kornacki S, Harpaz N, Bodian CA, Cohen LB, Miller KM, Aisenberg J. Is gastroduodenal biopsy safe in patients receiving aspirin and clopidogrel a prospective, randomized study involving 630 biopsies. J Clin Gastroenterol. 2011;45:228–233.